Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis

Abstract Background & objectives Obesity is a common comorbidity in heart failure, yet effective pharmacological options for weight loss in these patients are limited. Semaglutide, a glucagon-like peptide 1 receptor agonist, has shown promise for weight reduction in obese adults. This study aims...

Full description

Bibliographic Details

Published in:	BMC Cardiovascular Disorders
Main Authors:	Mahmoud Balata, Marc Ulrich Becher
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	Semaglutide Glucagon-like peptide 1 receptor agonist Weight reduction Heart failure
Online Access:	https://doi.org/10.1186/s12872-024-04275-2